Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900577 | 1.00 | GRIN2B (0.35) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL6900607 | 0.92 | MEN1 (0.36) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL15235879 | 0.85 | GRIN1 (0.31) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL6897245 | 0.84 | GRIN2B (0.35) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL6899921 | 0.83 | KMT2A (0.39) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL15235877 | 0.82 | KMT2A (0.34) | GRIN2BGRIN1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18387532 | 0.81 | SIGMAR1 (0.42) | — | |
| SCHEMBL1440297 | 0.81 | SIGMAR1 (0.42) | — | |
| SCHEMBL1440293 | 0.81 | SIGMAR1 (0.42) | — | |
| SCHEMBL31309170 | 0.81 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | GRIN2B 364/4885GRIN1 150/4885ALDH1A1 137/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | GRIN2B 453/4885GRIN1 157/4885ALDH1A1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.